Clinical-stage biotech stocks carry significant risks, but also offer explosive upside potential. These companies are built ...

A new scientific study into the weight loss drug Mounjaro has found that it may not lead to a worrying side effect as ...

The FDA has accepted the sNDA for nintedanib for children and adolescents 6 to 17 years of age with fibrosing interstitial lung disease.

During nintedanib (Ofev) treatment for interstitial lung disease associated with systemic sclerosis (SSc-ILD), clinicians prescribing the drug should be watchful for an unusual, indirect side ...

Nintedanib slows the deterioration of lung functionality in patients with limited cutaneous systemic sclerosis and interstitial lung disease, according to data published in Rheumatology.

Chinese scientists have developed a novel nanotherapy known as biomimetic extracellular vesicle spherical nucleic acids (BEV-SNAs), which has shown efficacy in treating idiopathic pulmonary fibrosis ...

Learn about cost and Ofev, financial and insurance assistance, ways to lower long-term costs, and more.

A woman who has lost roughly three stone while using weight-loss medication has revealed a more unusual side effect she’s ...

Although the nintedanib/afatinib combination (Combi70) did not lead to new or unexpected AEs, two of the first three treated patients discontinued owing to significant diarrhea and fatigue.

Met primary objective demonstrating nintedanib DPI was safe and well toleratedParticipants did not experience adverse events typically reported with oral nintedanibExpect to meet with the FDA in ...

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease ...

Addition of nintedanib improved cisplatin’s effects on suppressing the growth of cancer-cell spheroids and the invasion of cancer cells.